“This year continues trends that have been developing over the past few years,” said Baiju R. Shah, President of BioEnterprise. “There are more Midwestern deals each year that draw investment, the investment rounds are becoming larger, and the companies are attracting both regional and national investors for the financing.”
In addition to investments, 2007 has seen substantial exits, including MemberHealth (
By industry sub sector, the investment funding breaks down as follows:
· Biopharmaceutical companies: $591 million
· Medical device companies: $251 million
· Health care software and service companies: $158 million
The Midwest Health Care Venture Investment Report includes all reported numbers. For complete state and
To view additional data about
Table:
State | Through Q3 2007 | Through Q3 2006 | |||
$ Millions | # of | $ Millions | # of | ||
100.5 | 4 | 101.6 | 11 | ||
129.3 | 8 | 25.6 | 8 | ||
– | – | – | 0 | ||
– | – | – | 0 | ||
31.6 | 4 | 51.4 | 4 | ||
64.9 | 5 | 38.9 | 5 | ||
212.7 | 17 | 181.8 | 18 | ||
69.6 | 7 | 39.2 | 9 | ||
261.2 | 35 | 67.8 | 19 | ||
91.2 | 15 | 46.4 | 19 | ||
– | – | – | 0 | ||
39.7 | 9 | 11.5 | 5 | ||
Total | 1,000.4 | 104 | 563.6 | 98 |
Table:
Region | Through Q3 2007 | Through Q3 2006 | ||
$ Millions | # of | $ Millions | # of | |
100.5 | 4 | 101.6 | 11 | |
107.3 | 6 | 7.9 | 6 | |
22.0 | 2 | 17.7 | 2 | |
0.9 | 1 | 40.0 | 1 | |
5.7 | 2 | 11.4 | 3 | |
Detroit-Ann Arbor | 64.9 | 5 | 38.9 | 4 |
– | – | N/A | 1 | |
212.7 | 17 | 181.8 | 18 | |
57.6 | 7 | 20.2 | 8 | |
12.0 | 1 | 19.0 | 1 | |
61.0* | 7 | 10.6 | 3 | |
212.0 | 22 | 51.9 | 16 | |
13.2 | 7 | 5.3 | 10 | |
91.2 | 15 | 46.4 | 19 | |
– | 0 | – | 0 | |
39.7 | 9 | 11.5 | 5 | |
Total | 1,000.4 | 104 | 563.6 | 98 |
*Includes a deal from
Sources: Compiled by BioEnterprise team from Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, company press releases, www.biospace.com, and
About BioEnterprise
BioEnterprise is a business formation, recruitment, and acceleration effort designed to support the growth of bioscience companies. Located in
The initiative comprises the collective activities of BioEnterprise and its partners’ commercialization offices: the Case Office of Technology Transfer, Cleveland Clinic Innovations,